This study is currently not recruiting participants.

A Phase IIb dose ranging study of oral GSK1265744 in combination with nucleoside reverse transcriptase inhibitors for induction of HIV-1 virologic suppression followed by an evaluation of maintenance of virologic suppression when oral GSK1265744 is combi

Study on the Safety and Effectiveness of an Investigational Medication for HIV

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this study is to test the safety of GSK1265744 and how well it works to treat HIV.

Detailed description of study

The purpose of this study is to test the safety of GSK1265744 and how well it works to treat HIV.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: HIV
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the safety and effectiveness of an investigational medication for treating HIV. HIV, or Human Immunodeficiency Virus, is a virus that attacks the body's immune system. Understanding how this investigational medication works and ensuring it is safe is crucial for developing better treatments for HIV.

Participants in this study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will monitor participants to evaluate the medication's effects and safety.

  • Who can participate: Eligible participants are adults aged 18-65 who have been diagnosed with HIV. Additional eligibility criteria include stable health status and no recent participation in other clinical trials.
  • Study details: The study will monitor participants to evaluate the medication's effects and safety.
Updated on 19 Feb 2024. Study ID: 1208009262

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team